Press Release

Growing Prevalence of Chronic Diseases to Drive U.S Anemia Treatment Market at a Projected CAGR of 10.14% During 2025-30

The US Anemia Treatment Market size was valued at around USD 1.07 billion in 2024 and is projected to reach USD 1.98 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.14% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The US anemia treatment industry has substantially growth as a result of multiple factors such as accidents and increased surgical treatments, resulting in a growing incidence rate of blood disorders. This can be seen in iron deficiency, which is the most common reason behind anemia. For instance, as per the Centers for Disease Control and Prevention (CDC), about 5 million Americans suffer from the CDC. The number of anemia diagnoses has been increasing due to the rise in the aging population, especially among elderly people, who might have a higher risk of chronic diseases, such as kidney disease and cancer. Both of these conditions have higher chances of anemia.

The rising number of accidents and surgeries raises the need for anemia treatment. For instance, as per the National Trauma Institute, around 2 million people are treated with traumatic injuries annually in the U.S. Such injuries lead to a huge amount of blood loss and require immediate medical attention to control anemia. Due to the increased chance of getting anemia cases as a result of surgeries involving loss or post-surgical complications, replacement surgery at the joint and heart-related surgeries lead to blood-related complications. Hence Hospital and emergency care are growing to present better treatment solutions for anemia. As the demand for improved anemia management increases, pharmaceutical companies are introducing innovative therapies that offer enhanced and more convenient treatment options for patients, thereby expanding the market.

There have been continuous efforts by The U.S. Food and Drug Administration for approving anemia treatments and new drugs for it. FDA in recent times approved Jesduvroq tablets (daprodustat) for orally treating anemia which is related to chronic kidney disease mostly in adult patients, undergone kidney dialysis for at least four months. Research and development in this field have furthered the creation of personalized treatments for anemia including intravenous iron therapies, oral iron supplements with improved absorption, and advanced biologics such as erythropoiesis-stimulating agents (ESAs). Consequently, the U. S. Anemia Treatment Market is expected to grow significantly in the coming years as continued R&D investments lead to better solutions for patients and healthcare providers, further states the research report, U.S Anemia Treatment Market Analysis, 2025”

U.S Anemia Treatment Market Segmentation Analysis

Vitamin Deficiency Anemia Disease Type Holds the Largest Market Share

Based on disease type, the market is segmented into Iron deficiency anemia, sickle cell anemia, aplastic anemia, and vitamin deficiency anemia. Among all, vitamin deficiency anemia has the largest market share of around 30%. This is due to the lack of healthy diets, elderly populations, and patients with certain medical conditions leading to impaired nutrition absorption, which presents this problem. The treatment for vitamin deficiency anemia is normally straightforward, and oral supplements are being most popular. These are mostly in demand because they are cost-effective and easily maintain nutrition levels.

South Region Leads the U.S Anemia Treatment Industry

The south region holds the largest market share around 40% due to the higher number of population suffering from anemia which is caused by dietary deficiency, chronic disease, and a higher number of older adults who have less access to healthcare. A larger number of chronic diseases, such as diabetes and heart disease can increase the demand for disease treatment.

As the Centers for Disease Control and Prevention states anemia is highly preventive in the southern state, leading to major negative impacts on health. This, in return, increases the demand for this disease treatment, thereby increasing demand as well as driving the local market. Initiatives towards improving healthcare accessibility in this region are also helping support the growth of the overall market.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Pfizer, Novartis, Roche, Amgen, Bayer, Teva Pharmaceuticals, AMAG Pharmaceuticals, Akebia Therapeutics, Janssen Pharmaceuticals, Inc. Vigor Pharma Management Ltd. Abbot, Sanofi, and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the country?
4. How has the industry been evolving in terms of geography, and service adoption?
5. How has the competition been shaping up across the country?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?